anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
After the initial study injection at baseline, participants will receive their next study injection at Week 16. Participants in this study arm will also be issued a home monitoring device, which will allow for regular OCT monitoring (at least 5 times a week) at home.
Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
<P>PROBLEM TO BE SOLVED: To provide an oral composition effective for the prevention or treatment of the gastrointestinal functional deteriorations such as a heavy feeling in stomach, an uncomfortable feeling in stomach, an abdominal flatulent feeling, anorexia, a belch, etc., caused by taking a high fat food, an unbalanced diet, etc.  <P>SOLUTION: This oral composition is characterized by containing turmeric and dried ginger. Preferably the composition contains 0.2-5 pts. mass dried ginger based on 1 pt. mass turmeric.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
In a 24-month study in rats (10, 45, and 200 mg/kg; 0.3, 1, and 6 times the maximum recommended human dose on the basis of mg/meter2 of surface area), the incidence of liver carcinoma was significantly increased at 6 times the maximum recommended human dose in males and females. A statistically significant increase in pancreatic carcinomas occurred in males at 1 and 6 times the maximum recommended human dose; there were also increases in pancreatic adenomas and benign testicular interstitial cell tumors at 6 times the maximum recommended human dose in males. In a second 24-month study in a different strain of rats (doses of 10 and 60 mg/kg; 0.3 and 2 times the maximum recommended human dose based on mg/meter2 surface area), there were significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in interstitial cell tumors of the testes at 2 times the maximum recommended human dose.

A comparative carcinogenicity study was done in rats comparing three drugs: fenofibrate (10 and 70 mg/kg; 0.3 and 1.6 times the maximum recommended human dose), clofibrate (400 mg/kg; 1.6 times the human dose), and gemfibrozil (250 mg/kg; 1.7 times the human dose) (multiples based on mg/meter2 surface area). Pancreatic acinar adenomas were increased in males and females on fenofibrate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with gemfibrozil while testicular interstitial cell tumors were increased in males on all three drugs.

In a 21-month study in mice at doses of 10, 45, and 200 mg/kg (approximately 0.2, 0.7 and 3 times the maximum recommended human dose on the basis of mg/meter2 surface area), there were statistically significant increases in liver carcinoma at 3 times the maximum recommended human dose in both males and females. In a second 18-month study at the same doses, there was a significant increase in liver carcinoma in male mice and liver adenoma in female mice at 3 times the maximum recommended human dose.

Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual. 

Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis.
A therapy system features at least one therapist computer to create or maintain therapy programs and at least one patient computer. In the course of the therapy, the patient computer is connected with a therapy sensor that again is connected with the therapist computer via a data network. A communication module controls the data flow from the therapist computer to the patient computer. The communication module is designed in such a way that in the beginning of a therapy session a configuration packet is transmitted from the therapist computer to the patient computer that manages the release of at least one certain therapy program already preloaded on the patient computer. Conducting a therapy method using this therapy system, at first a computer-based executable therapy program is created and installed on at least one patient computer. Then a therapy plan is created, therapy information that mirror the therapy plan are transmitted from the therapist computer to the patient computer. Then, this therapy plan is executed by the patient via the patient computer. Configuration data are transmitted as therapy information that in the beginning of a therapy session control the release of at least one certain therapy program already preloaded on the patient computer. Therapy system and therapy method only require little effort concerning the data communication when adapting the therapy.
Patient will have a "No split cast" long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm.
Many evidence-based mental health interventions have been developed to address the negative outcomes associated with child exposure to early adversity and trauma. Despite these promising advances, however, the majority of children served in publicly funded mental health systems do not receive evidence-based programs (EBPs). To address this research-to-practice gap, several large-scale, system-driven implementation efforts of multiple trauma EBPs have been launched over the last decade, including in the states of California and Arkansas. Though these system-driven initiatives often increase EBP delivery in community settings following the initial implementation push, long-term sustainment of EBP delivery is low. Workforce risk factors, such as provider burnout leading to turnover, have been identified as contributing to the poor long-term sustainment of trauma EBPs. Therefore, an important step to consider in supporting the longterm sustainment of child trauma EBPs is to develop implementation strategies that target provider burnout and organizational climate factors associated with decreased provider retention. This study will develop and pilot a package of implementation strategies, "Supporting Providers \& Preventing the Overwhelming of Resources in Trauma Systems" (SUPPORTS), aimed increasing the sustained delivery of trauma EBPs by addressing the factors associated with provider retention related to burnout. The development of SUPPORTS will be informed by a needs assessment conducted with programs involved with the multiple-EBP implementation efforts in California and Arkansas. A small randomized controlled pilot will then be conducted in California.
Diagnoses of marginal zone lymphomas based on the last WHO classification of haematolymphoid tumours at the time of occurrence of the disease. FISH utilizes Vysis' Dual-Color Break-Apart Rearrangement Probes to detect BCL6 gene alterations. FISH patterns have been interpreted following established protocols.
The application discloses a monoclonal antibody specifically binding to coxsackievirus A6 and application thereof. The monoclonal antibody comprises a light chain and a heavy chain, wherein the complementarity determining region of the heavy chain comprises HCDR1, HCDR2 and HCDR3, the complementarity determining region of the light chain comprises LCDR1, LCDR2 and LCDR3, and the sequence of the HCDR1 comprises any one of the sequences shown in SEQ ID No. 1-SEQ ID No. 3; the sequence of HCDR2 includes any one of the sequences shown in SEQ ID No. 4-SEQ ID No. 6; the sequence of HCDR3 includes any one of the sequences shown in SEQ ID No. 7-SEQ ID No. 9. The monoclonal antibody has good specificity and sensitivity and virus neutralization capability, and has great potential in virus identification, diagnosis, treatment and multivalent vaccine development.
PURPOSE:An inhibitor for dandruff capable of preventing a scurfy disease of the scalp (dandruff disease) and urtication caused by it by administration to the affected part, and thoroughly satisfactory with respect to safety, stability of pharmaceutical manufacturing, smell, etc., comprising an antagonist of a histamine H2 acceptor as an active ingredient. CONSTITUTION:An inhibitor for dandruff, e.g., a medicine for hair and/or scalp, shampoo, hair dressing, etc., comprising ordinarily >=0.5wt% preferably 1-20wt% antagonist of a histamine H2 acceptor, e.g., cimetidine, metiamide, burimamide, ranitidine, etc. as an active ingredient. The use of the inhibitor for dandruff according to a conventional way can prevent thoroughly dandruff and urtication caused by it. The antagonist of a histamine H2 acceptor is extremly stable in a solvent, e.g., water, an alcohol, etc. and is excellent with respect to safety and smell. It can be used together with a conventional inhibitor for dandruff, especially germicide, and in this case better results can be obtained.
FIELD: medicine.SUBSTANCE: for complex empirical antibacterial therapy of implant-associated orthopedic infections, bone defect replacement with a cement spacer is performed. Then the wound is sutured. Antibacterial therapy is prescribed, which has simultaneous local and systemic effect on the focus of infection. At that, an antibacterial drug is added to the cement when the spacer is mixed and injected systemically after the operation. This antibacterial drug is allowed for regular use and is characterized by the presence of a freeze-dried form, thermostability, water solubility, a wide range of activity, including methicillin-resistant Staphylococcus. Moreover, the systemic therapy is complemented with an antibiotic having a synergic action in terms of leading pathogens of the implant-associated infection, but belonging to another group.EFFECT: invention allows to increase the effectiveness of etiotropic antibacterial therapy for implant-associated orthopedic infections.1 ex
The invention relates to a STK10 diagnostic kit, an STK10 inhibitor and application of a PLK1 inhibitor in treating leukemia. The invention discovers that STK10mRNA is remarkably and highly expressed in an AML leukemia sample and is positively correlated with the bad prognosis of an AML patient. When STK10 gene is knocked out or an inhibitor interferes with the function of STK10, apoptosis can be obviously caused in vitro, tumor load can be reduced in vivo, and the survival period can be prolonged. The therapeutic effect is closely related to the expression quantity and the positioning of STK10 in cells, so that the targeted therapy can be realized aiming at the expression quantity and the positioning of the STK 10. STK10 blocks cell cycle progression in a synergistic or antagonistic manner during SB633825 and Volasertib combination treatment, resulting in cell cycle disorders, which synergistically promote apoptosis. Based on MLL-AF9AML, MV411-GLCDX, THP1-GLCDX, ALLPDX and DLBCLPDX mouse models, the double-drug combination effectively prolongs the survival time of mice and reduces the tumor load. The results show that the STK10 inhibitor and the PLK1 inhibitor can be used for cooperatively treating AML and other leukemia, and have good application prospects.
OBJECTIVE: To explore the clinical and genetic features of two Chinese pedigrees affected with Autosomal dominant intellectual developmental disorder 49 (MRD49).
METHODS: Two MRD49 pedigrees which were admitted to the Children's Hospital Affiliated to Shandong University respectively on January 28, 2021 and November 10, 2022 were selected as the study subjects. Clinical data of the two pedigrees were collected and analyzed. Genomic DNA was extracted from peripheral blood samples of the probands and their family members. The probands were subjected to mutational analysis by high-throughput sequencing. Candidate variants were validated using real-time fluorescence quantitative PCR (q-PCR) or Sanger sequencing and bioinformatic analysis. This study was approved by the Medical Ethics Committee of the Children's Hospital Affiliated to Shandong University (Ethics No. SDFE-IRB/T-2022002).
RESULTS: Proband 1 had presented with language delay, motor retardation and intellectual disability, and his maternal grandmother, mother, aunt and cousin all had various degrees of intellectual disability. Sequencing results showed that proband 1 had deletion of exons 3 ~ 7 of the TRIP12 gene. q-PCR verification showed that his mother, aunt, maternal grandmother and cousin had all harbored the same deletion. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as pathogenic (PVS1+PM2_Supporting+PP1). Proband 2, who had mainly presented with language delay, motor retardation and intellectual disability, and was found to harbor a heterozygous c.3010C>T (p.Arg1004*) variant of the TRIP12 gene, which was verified to be de novo in origin. Based on the guidelines from the ACMG, the variant was classified as pathogenic (PVS1+PS2+PM2_Supporting).
CONCLUSION: This study had diagnosed two MRD49 families through high-throughput sequencing. Above findings have enriched the phenotypic and mutational spectrum of MRD49 in China, which has also facilitated genetic counseling for the two pedigrees.
The present application relates to apparatus and methods for objective visual acuity measurement using a dynamic velocity threshold filter. Ocular tremor (OKN) is the movement of the eyes caused by tracking a moving object in the visual field. It is characterized by alternating smooth pursuits in one direction and saccadic movements in the other direction. The presence or absence of OKN indicates whether the motor stimulus is visible to the observer without explicit cooperation by the observer. It may be a tool for objective visual acuity assessment for patients lacking cognitive, attention and linguistic abilities, such as young children. Since head movements and unstable eye fixations of the patient may occur during the test, which often cause noise and irrelevant activity in the reaction, the identification of the presence/absence of OKN is made a challenging task. The present invention uses a Dynamic Velocity Threshold (DVT) filter to provide a system and method for a fast and reliable OKN test and quantitative assessment of visual acuity.
This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with hearing aids after a 6-month delay. Their performance was monitored 6-months pre-fitting and for the 6 months after the fitting.
Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2% to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H 2antagonists (see DOSAGE AND ADMINISTRATIONsection). Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug. 

Bone marrow suppression (primarily neutropenia) is dose-dependent and is the dose-limiting toxicity. Neutrophil nadirs occurred at a median of 11 days. Paclitaxel should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm 3(<1,000 cells/mm 3for patients with KS). Frequent monitoring of blood counts should be instituted during paclitaxel treatment. Patients should not be re-treated with subsequent cycles of paclitaxel until neutrophils recover to a level >1,500 cells/mm 3(>1,000 cells/mm 3for patients with KS) and platelets recover to a level >100,000 cells/mm 3. 

Severe conduction abnormalities have been documented in <1% of patients during paclitaxel therapy and in some cases requiring pacemaker placement. If patients develop significant conduction abnormalities during paclitaxel infusion, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with paclitaxel.
The spine is the central supporting structure of the body and for the torso in particular, allowing for flexibility and shock absorption, as well as routing and protecting the spinal cord and supporting the head and upper limbs for sensory and motor functions. In this perspective the evaluation of its movements in a global and segmental contribution is of paramount importance and cannot be separated by the other tasks. The locomotor function was the first one targeted by human motion analysis and still represent the main application in the rehabilitation. Optoelectronic systems are the gold standard technique for this assessment and specific protocols are available and applied. Traditional stereophotogrammetric models were used to assess the kinematics of pelvis, hip, knee, ankle, trunk (considered as a single rigid segment that does not provide information on kinematic changes within the spine). Indeed, it is relevant to understand the integrated and synergic motion of the spine and other body segment for a variety of applications, such as clinical diagnosis, endoprosthesis design, and the evaluation of treatment outcomes. Therefore, an accurate trunk motion analysis may be useful during medical diagnostic-therapeutic process. The aim of this study is introducing a new protocol consisting of a marker set, i.e. an innovative and integrated biomechanical model of the human body for the global analysis of spine and body movement during gait allows for a more detailed evaluation of the motor behavior and its abnormalities to better characterize the functionality of the spine at the level of its three main segments (upper thoracic, lower thoracic and lumbar), both on the sagittal, frontal and transversal plane, during walking. The development of a new protocol of analysis requires the validation before its definitive and clinical application. More in detail, the validation should be carried out in terms of both comparisons with reference absolute measures and the evaluation of its repeatability with healthy subjects.
MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.
Urinary incontinence is a global condition and its prevalence increases with age. It impairs quality of life of patients and has a significant burden on the health care system. Stress urinary incontinence (SUI) is defined as involuntary leakage of urine when there is an increase in pressure on the bladder, i.e. during exercise, coughing or sneezing. It is the commonest form of urinary incontinence and affects around 50% of women with symptoms of incontinence.

The development of mid urethral tapes (e.g. the tension free vaginal tape \[TVT\]) in 1998 has greatly changed clinical practice. The introduction of TVTs has reduced the average length of hospital stay for patients undergoing surgical treatment of SUI by over 50%. As a result, the hospital bed occupancy for the treatment of SUI has decreased by a similar amount. Studies have shown it to have similar effectiveness to the main alternative surgical treatments in SUI.

In Gloucestershire Royal Hospital, we perform the procedure as a daycase with local anaesthetic infiltration under sedation. Routine cystoscopy is performed as a part of the procedure to exclude bladder trauma. The bladder is emptied at the end of procedure. Patients are then allowed to drink as normal and post void residuals are checked before discharge to rule out any problems emptying the bladder. It has been observed that the major limiting factor in early discharge of patients is the time to first void following surgery. As the patients are starved for surgery, they are often dehydrated and therefore require enough oral fluids to rehydrate and fill their bladder in order to void. If we can somehow reduce this waiting period, we can discharge patients sooner improving their experience with the surgery. We would like to examine whether filling up the bladder intra-operatively with intravenous fluid will reduce this time limiting step.
This study aims to contribute to the knowledge about lacking or contradictory effects of benzodiazepine on hyperaroused or aggressive behaviour in persons with intellectual disability (ID). We conducted a retrospective and natural case study in a person with mild ID and multiple adverse childhood experiences (ACE), using routine diary data consisting of 275 days including 113 consecutive days under benzodiazepine medication. The medication effects were documented as "calm / relaxed", "fretful / distressed" and "sleep / doze". Transitions between these were modelled using Markov chains. Differences in transitions were analysed using Chi-Square test for homogeneity. The results show a significantly reduced stability of mood and increased distressed behaviour under benzodiazepine. This is in line with reports about the effects of psychotropic medication in patients with ID and challenging behaviour. Besides other influences on unexpected medication effects, a possible dissociative identity disorder is discussed as an additional explanation.